+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Checkpoint Inhibitors"

Checkpoint Inhibitors Market Report 2026 - Product Thumbnail Image

Checkpoint Inhibitors Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
Checkpoint Inhibitors - Competitive Landscape, 2026 - Product Thumbnail Image

Checkpoint Inhibitors - Competitive Landscape, 2026

  • Report
  • January 2026
  • 180 Pages
  • Global
From
From
PD-1/PD-L1 Checkpoint Inhibitors Market - Global Forecast 2026-2032 - Product Thumbnail Image

PD-1/PD-L1 Checkpoint Inhibitors Market - Global Forecast 2026-2032

  • Report
  • September 2026
  • 192 Pages
  • Global
From
From
Checkpoint Inhibitor Refractory Cancer Market Report 2026 - Product Thumbnail Image

Checkpoint Inhibitor Refractory Cancer Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
From
From
From
From
Precision Oncology Market - Global Forecast to 2036 - Product Thumbnail Image

Precision Oncology Market - Global Forecast to 2036

  • Report
  • March 2026
  • 288 Pages
  • Global
From
Immunotherapy Platforms Market - Global Forecast to 2036 - Product Thumbnail Image

Immunotherapy Platforms Market - Global Forecast to 2036

  • Report
  • March 2026
  • 320 Pages
  • Global
From
Loading Indicator

The Checkpoint Inhibitors market is a subset of the Oncology Drugs market, which focuses on treatments for cancer. Checkpoint Inhibitors are a type of immunotherapy, which works by blocking certain proteins that act as “checkpoints” in the body’s immune system. By blocking these checkpoints, the body’s immune system is able to recognize and attack cancer cells. This type of therapy has been found to be effective in treating a variety of cancers, including melanoma, non-small cell lung cancer, and bladder cancer. The Checkpoint Inhibitors market is highly competitive, with many companies developing and marketing their own products. Some of the major players in the market include Merck, Bristol-Myers Squibb, Roche, AstraZeneca, and Pfizer. Show Less Read more